Cargando…

The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells

Glioblastoma is one of the most common malignant tumors in the nervous system in both adult and pediatric patients. Studies suggest that abnormal activation of receptor tyrosine kinases contributes to pathological development of glioblastoma. However, current therapies targeting tyrosine kinase rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Junxia, Zhou, Qiang, Gao, Ge, Wang, Yanfen, Fang, Zhihui, Li, Guanlin, Yu, Mengfei, Kong, Lingfei, Xing, Ying, Gao, Xiaoqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4218911/
https://www.ncbi.nlm.nih.gov/pubmed/25378936
http://dx.doi.org/10.2147/OTT.S67556
_version_ 1782342495666962432
author Zhang, Junxia
Zhou, Qiang
Gao, Ge
Wang, Yanfen
Fang, Zhihui
Li, Guanlin
Yu, Mengfei
Kong, Lingfei
Xing, Ying
Gao, Xiaoqun
author_facet Zhang, Junxia
Zhou, Qiang
Gao, Ge
Wang, Yanfen
Fang, Zhihui
Li, Guanlin
Yu, Mengfei
Kong, Lingfei
Xing, Ying
Gao, Xiaoqun
author_sort Zhang, Junxia
collection PubMed
description Glioblastoma is one of the most common malignant tumors in the nervous system in both adult and pediatric patients. Studies suggest that abnormal activation of receptor tyrosine kinases contributes to pathological development of glioblastoma. However, current therapies targeting tyrosine kinase receptors have poor therapeutic outcomes. Here, we examined anticancer effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, on glioblastoma cells both in the U87MG cell line and in the mouse xenograft model. We showed that ponatinib treatment reduced cell viability and induced cell apoptosis in a dose-dependent manner in U87MG cells. In addition, ponatinib suppressed migration and invasion of U87MG cells effectively. Furthermore, ponatinib-treated tumors showed an obvious reduction of tumor volume and an increase of apoptosis as compared with vehicle-treated tumors in the mouse xenograft model. These findings support a potential application of ponatinib as a chemotherapeutic option against glioblastoma cells.
format Online
Article
Text
id pubmed-4218911
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-42189112014-11-06 The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells Zhang, Junxia Zhou, Qiang Gao, Ge Wang, Yanfen Fang, Zhihui Li, Guanlin Yu, Mengfei Kong, Lingfei Xing, Ying Gao, Xiaoqun Onco Targets Ther Original Research Glioblastoma is one of the most common malignant tumors in the nervous system in both adult and pediatric patients. Studies suggest that abnormal activation of receptor tyrosine kinases contributes to pathological development of glioblastoma. However, current therapies targeting tyrosine kinase receptors have poor therapeutic outcomes. Here, we examined anticancer effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, on glioblastoma cells both in the U87MG cell line and in the mouse xenograft model. We showed that ponatinib treatment reduced cell viability and induced cell apoptosis in a dose-dependent manner in U87MG cells. In addition, ponatinib suppressed migration and invasion of U87MG cells effectively. Furthermore, ponatinib-treated tumors showed an obvious reduction of tumor volume and an increase of apoptosis as compared with vehicle-treated tumors in the mouse xenograft model. These findings support a potential application of ponatinib as a chemotherapeutic option against glioblastoma cells. Dove Medical Press 2014-10-30 /pmc/articles/PMC4218911/ /pubmed/25378936 http://dx.doi.org/10.2147/OTT.S67556 Text en © 2014 Zhang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Zhang, Junxia
Zhou, Qiang
Gao, Ge
Wang, Yanfen
Fang, Zhihui
Li, Guanlin
Yu, Mengfei
Kong, Lingfei
Xing, Ying
Gao, Xiaoqun
The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells
title The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells
title_full The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells
title_fullStr The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells
title_full_unstemmed The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells
title_short The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells
title_sort effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human u87 malignant glioblastoma cells
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4218911/
https://www.ncbi.nlm.nih.gov/pubmed/25378936
http://dx.doi.org/10.2147/OTT.S67556
work_keys_str_mv AT zhangjunxia theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT zhouqiang theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT gaoge theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT wangyanfen theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT fangzhihui theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT liguanlin theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT yumengfei theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT konglingfei theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT xingying theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT gaoxiaoqun theeffectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT zhangjunxia effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT zhouqiang effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT gaoge effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT wangyanfen effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT fangzhihui effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT liguanlin effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT yumengfei effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT konglingfei effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT xingying effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells
AT gaoxiaoqun effectsofponatinibamultitargetedtyrosinekinaseinhibitoragainsthumanu87malignantglioblastomacells